Epigenetics and Human Infectious Diseases

Epigenetics in Human Disease

Volumn , Issue , 2012, Pages 415-441

  Niller, Hans Helmut ^a   Minarovits, Janos ^b  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b NATIONAL CENTER FOR EPIDEMIOLOGY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882531979     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-388415-2.00021-4     Document Type: Chapter

References (226)

1. Minarovits J. Microbe-induced epigenetic alterations in host cells: the coming era of patho-epigenetics of microbial infections. A review. Acta Microbiol Immunol Hung 2009, 56:1-19.
2. Lopez-Rubio J.J., Riviere L., Scherf A. Shared epigenetic mechanisms control virulence factors in protozoan parasites. Curr Opin Microbiol 2007, 10:560-568.
3. Verstrepen K.J., Fink G.R. Genetic and epigenetic mechanisms underlying cell-surface variability in protozoa and fungi. Annu Rev Genet 2009, 43:1-24.
4. Dixon S.E., Stilger K.L., Elias E.V., Naguleswaran A., Sullivan W.J. A decade of epigenetic research in Toxoplasma gondii. Mol Biochem Parasitol 2010, 173:1-9.
5. Merrick C.J., Duraisingh M.T. Epigenetics in Plasmodium: what do we really know?. Eukaryot Cell 2010, 9:1150-1158.
6. da Rosa J.L., Kaufman P.D. Chromatin-mediated Candida albicans virulence. Biochim Biophys Acta 2012, 1819:349-355.
7. Minarovits J. Epigenotypes of latent herpesvirus genomes. Curr Top Microbiol Immunol 2006, 310:61-80.
8. Bloom D.C., Giordani N.V., Kwiatkowski D.L. Epigenetic regulation of latent HSV-1 gene expression. Biochim Biophys Acta 2010, 1799:246-256.
9. Horwitz G.A., Zhang K., McBrian M.A., Grunstein M., Kurdistani S.K., Berk A.J. Adenovirus small e1a alters global patterns of histone modification. Science 2008, 321:1084-1085.
10. Ferrari R., Pellegrini M., Horwitz G.A., Xie W., Berk A.J., Kurdistani S.K. Epigenetic reprogramming by adenovirus e1a. Science 2008, 321:1086-1088.
11. Pihlstrom B.L., Michalowicz B.S., Johnson N.W. Periodontal diseases. Lancet 2005, 366:1809-1820.
12. Darveau R.P. The oral microbial consortium's interaction with the periodontal innate defense system. DNA Cell Biol 2009, 28:389-395.
13. Pedra J.H., Cassel S.L., Sutterwala F.S. Sensing pathogens and danger signals by the inflammasome. Curr Opin Immunol 2009, 21:10-16.
14. Manavalan B., Basith S., Choi S. Similar Structures but Different Roles - An Updated Perspective on TLR Structures. Front Physiol 2011, 2:41.
15. Philbin V.J., Levy O. Developmental biology of the innate immune response: implications for neonatal and infant vaccine development. Pediatr Res 2009, 65:98R-105R.
16. Yin L., Chung W.O. Epigenetic regulation of human beta-defensin 2 and CC chemokine ligand 20 expression in gingival epithelial cells in response to oral bacteria. Mucosal Immunol 2011, 4:409-419.
17. Kurita-Ochiai T., Fukushima K., Ochiai K. Volatile fatty acids, metabolic by-products of periodontopathic bacteria, inhibit lymphocyte proliferation and cytokine production. J Dent Res 1995, 74:1367-1373.
18. Niederman R., Buyle-Bodin Y., Lu B.Y., Robinson P., Naleway C. Short-chain carboxylic acid concentration in human gingival crevicular fluid. J Dent Res 1997, 76:575-579.
19. Tonetti M., Eftimiadi C., Damiani G., Buffa P., Buffa D., Botta G.A. Short chain fatty acids present in periodontal pockets may play a role in human periodontal diseases. J Periodontal Res 1987, 22:190-191.
20. Imai K., Ochiai K., Okamoto T. Reactivation of latent HIV-1 infection by the periodontopathic bacterium Porphyromonas gingivalis involves histone modification. J Immunol 2009, 182:3688-3695.
21. Riggs M.G., Whittaker R.G., Neumann J.R., Ingram V.M. n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. Nature 1977, 268:462-464.
22. Sealy L., Chalkley R. The effect of sodium butyrate on histone modification. Cell 1978, 14:115-121.
23. Myzak M.C., Ho E., Dashwood R.H. Dietary agents as histone deacetylase inhibitors. Mol Carcinog 2006, 45:443-446.
24. Bobetsis Y.A., Barros S.P., Lin D.M., Weidman J.R., Dolinoy D.C., Jirtle R.L., et al. Bacterial infection promotes DNA hypermethylation. J Dent Res 2007, 86:169-174.
25. Paschos K., Allday M.J. Epigenetic reprogramming of host genes in viral and microbial pathogenesis. Trends Microbiol 2010, 18:439-447.
26. Freitag N.E., Port G.C., Miner M.D. Listeria monocytogenes - from saprophyte to intracellular pathogen. Nat Rev Microbiol 2009, 7:623-628.
27. Hamon M.A., Batsche E., Regnault B., Tham T.N., Seveau S., Muchardt C., et al. Histone modifications induced by a family of bacterial toxins. Proc Natl Acad Sci USA 2007, 104:13467-13472.
28. Schroeder G.N., Hilbi H. Molecular pathogenesis of Shigella spp.: controlling host cell signaling, invasion, and death by type III secretion. Clin Microbiol Rev 2008, 21:134-156.
29. Arbibe L., Kim D.W., Batsche E., Pedron T., Mateescu B., Muchardt C., et al. An injected bacterial effector targets chromatin access for transcription factor NF-kappaB to alter transcription of host genes involved in immune responses. Nat Immunol 2007, 8:47-56.
30. Ismail N., Bloch K.C., McBride J.W. Human ehrlichiosis and anaplasmosis. Clin Lab Med 2010, 30:261-292.
31. Garcia-Garcia J.C., Barat N.C., Trembley S.J., Dumler J.S. Epigenetic silencing of host cell defense genes enhances intracellular survival of the rickettsial pathogen Anaplasma phagocytophilum. PLoS Pathog 2009, 5. e1000488.
32. Uemura N., Okamoto S., Yamamoto S., Matsumura N., Yamaguchi S., Yamakido M., et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001, 345:784-789.
33. Nardone G., Compare D., De Colibus P., de Nucci G., Rocco A. Helicobacter pylori and epigenetic mechanisms underlying gastric carcinogenesis. Dig Dis 2007, 25:225-229.
34. Yamamoto E., Suzuki H., Takamaru H., Yamamoto H., Toyota M., Shinomura Y. Role of DNA methylation in the development of diffuse-type gastric cancer. Digestion 2011, 83:241-249.
35. Ding S.Z., Goldberg J.B., Hatakeyama M. Helicobacter pylori infection, oncogenic pathways and epigenetic mechanisms in gastric carcinogenesis. Future Oncol 2010, 6:851-862.
36. Suerbaum S., Michetti P. Helicobacter pylori infection. N Engl J Med 2002, 347:1175-1186.
37. Hatakeyama M. Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat Rev Cancer 2004, 4:688-694.
38. Umeda M., Murata-Kamiya N., Saito Y., Ohba Y., Takahashi M., Hatakeyama M. Helicobacter pylori CagA causes mitotic impairment and induces chromosomal instability. J Biol Chem 2009, 284:22166-22172.
39. Kang G.H., Shim Y.H., Jung H.Y., Kim W.H., Ro J.Y., Rhyu M.G. CpG island methylation in premalignant stages of gastric carcinoma. Cancer Res 2001, 61:2847-2851.
40. Kang G.H., Lee S., Kim J.S., Jung H.Y. Profile of aberrant CpG island methylation along the multistep pathway of gastric carcinogenesis. Lab Invest 2003, 83:635-641.
41. Yamashita S., Tsujino Y., Moriguchi K., Tatematsu M., Ushijima T. Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2'-deoxycytidine treatment and oligonucleotide microarray. Cancer Sci 2006, 97:64-71.
42. Maekita T., Nakazawa K., Mihara M., Nakajima T., Yanaoka K., Iguchi M., et al. High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin Cancer Res 2006, 12:989-995.
43. Nakajima T., Maekita T., Oda I., Gotoda T., Yamamoto S., Umemura S., et al. Higher methylation levels in gastric mucosae significantly correlate with higher risk of gastric cancers. Cancer Epidemiol Biomarkers Prev 2006, 15:2317-2321.
44. Perri F., Cotugno R., Piepoli A., Merla A., Quitadamo M., Gentile A., et al. Aberrant DNA methylation in non-neoplastic gastric mucosa of H. Pylori infected patients and effect of eradication. Am J Gastroenterol 2007, 102:1361-1371.
45. Kaise M., Yamasaki T., Yonezawa J., Miwa J., Ohta Y., Tajiri H. CpG island hypermethylation of tumor-suppressor genes in H. pylori-infected non-neoplastic gastric mucosa is linked with gastric cancer risk. Helicobacter 2008, 13:35-41.
46. Park S.Y., Yoo E.J., Cho N.Y., Kim N., Kang G.H. Comparison of CpG island hypermethylation and repetitive DNA hypomethylation in premalignant stages of gastric cancer, stratified for Helicobacter pylori infection. J Pathol 2009, 219:410-416.
47. Compare D., Rocco A., Liguori E., D'Armiento F.P., Persico G., Masone S., et al. Global DNA hypomethylation is an early event in Helicobacter pylori-related gastric carcinogenesis. J Clin Pathol 2011, 64:677-682.
48. Waki T., Tamura G., Tsuchiya T., Sato K., Nishizuka S., Motoyama T. Promoter methylation status of E-cadherin, hMLH1, and p16 genes in nonneoplastic gastric epithelia. Am J Pathol 2002, 161:399-403.
49. Chan A.O., Peng J.Z., Lam S.K., Lai K.C., Yuen M.F., Cheung H.K., et al. Eradication of Helicobacter pylori infection reverses E-cadherin promoter hypermethylation. Gut 2006, 55:463-468.
50. Leung W.K., Man E.P., Yu J., Go M.Y., To K.F., Yamaoka Y., et al. Effects of Helicobacter pylori eradication on methylation status of E-cadherin gene in noncancerous stomach. Clin Cancer Res 2006, 12:3216-3221.
51. Nakajima T., Enomoto S., Yamashita S., Ando T., Nakanishi Y., Nakazawa K., et al. Persistence of a component of DNA methylation in gastric mucosae after Helicobacter pylori eradication. J Gastroenterol 2010, 45:37-44.
52. Kabir S. Effect of Helicobacter pylori eradication on incidence of gastric cancer in human and animal models: underlying biochemical and molecular events. Helicobacter 2009, 14:159-171.
53. Niwa T., Tsukamoto T., Toyoda T., Mori A., Tanaka H., Maekita T., et al. Inflammatory processes triggered by Helicobacter pylori infection cause aberrant DNA methylation in gastric epithelial cells. Cancer Res 2010, 70:1430-1440.
54. Kang H.Y., Kim N., Park Y.S., Hwang J.H., Kim J.W., Jeong S.H., et al. Progression of atrophic gastritis and intestinal metaplasia drives Helicobacter pylori out of the gastric mucosa. Dig Dis Sci 2006, 51:2310-2315.
55. Ushijima T. Epigenetic field for cancerization. J Biochem Mol Biol 2007, 40:142-150.
56. Guilford P., Hopkins J., Harraway J., McLeod M., McLeod N., Harawira P., et al. E-cadherin germline mutations in familial gastric cancer. Nature 1998, 392:402-405.
57. Grady W.M., Willis J., Guilford P.J., Dunbier A.K., Toro T.T., Lynch H., et al. Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat Genet 2000, 26:16-17.
58. Machado J.C., Oliveira C., Carvalho R., Soares P., Berx G., Caldas C., et al. E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. Oncogene 2001, 20:1525-1528.
59. Miyazaki T., Murayama Y., Shinomura Y., Yamamoto T., Watabe K., Tsutsui S., et al. E-cadherin gene promoter hypermethylation in H. pylori-induced enlarged fold gastritis. Helicobacter 2007, 12:523-531.
60. Terres A.M., Pajares J.M., O'Toole D., Ahern S., Kelleher D. H pylori infection is associated with downregulation of E-cadherin, a molecule involved in epithelial cell adhesion and proliferation control. J Clin Pathol 1998, 51:410-412.
61. Chan A.O., Lam S.K., Wong B.C., Wong W.M., Yuen M.F., Yeung Y.H., et al. Promoter methylation of E-cadherin gene in gastric mucosa associated with Helicobacter pylori infection and in gastric cancer. Gut 2003, 52:502-506.
62. Yamashita K., Sakuramoto S., Watanabe M. Genomic and epigenetic profiles of gastric cancer: potential diagnostic and therapeutic applications. Surg Today 2011, 41:24-38.
63. Nakajima T., Yamashita S., Maekita T., Niwa T., Nakazawa K., Ushijima T. The presence of a methylation fingerprint of Helicobacter pylori infection in human gastric mucosae. Int J Cancer 2009, 124:905-910.
64. Shin C.M., Kim N., Jung Y., Park J.H., Kang G.H., Park W.Y., et al. Genome-wide DNA methylation profiles in noncancerous gastric mucosae with regard to Helicobacter pylori infection and the presence of gastric cancer. Helicobacter 2011, 16:179-188.
65. Yan J., Zhang M., Zhang J., Chen X., Zhang X. Helicobacter pylori infection promotes methylation of WWOX gene in human gastric cancer. Biochem Biophys Res Commun 2011, 408:99-102.
66. Takeshima H., Yamashita S., Shimazu T., Niwa T., Ushijima T. The presence of RNA polymerase II, active or stalled, predicts epigenetic fate of promoter CpG islands. Genome Res 2009, 19:1974-1982.
67. Takeshima H., Ushijima T. Methylation destiny: Moira takes account of histones and RNA polymerase II. Epigenetics 2010, 5:89-95.
68. Vitkute J., Stankevicius K., Tamulaitiene G., Maneliene Z., Timinskas A., Berg D.E., et al. Specificities of eleven different DNA methyltransferases of Helicobacter pylori strain 26695. J Bacteriol 2001, 183:443-450.
69. Alves M.K., Ferrasi A.C., Lima V.P., Ferreira M.V., de Moura Campos Pardini M.I., Rabenhorst S.H. Inactivation of COX-2, HMLH1 and CDKN2A Gene by Promoter Methylation in Gastric Cancer: Relationship with Histological Subtype, Tumor Location and Helicobacter pylori Genotype. Pathobiology 2011, 78:266-276.
70. Bussiere F.I., Michel V., Memet S., Ave P., Vivas J.R., Huerre M., et al. H. pylori-induced promoter hypermethylation downregulates USF1 and USF2 transcription factor gene expression. Cell Microbiol 2010, 12:1124-1133.
71. Touati E. When bacteria become mutagenic and carcinogenic: lessons from H. pylori. Mutat Res 2010, 703:66-70.
72. Sepulveda A.R., Yao Y., Yan W., Park D.I., Kim J.J., Gooding W., et al. CpG methylation and reduced expression of O6-methylguanine DNA methyltransferase is associated with Helicobacter pylori infection. Gastroenterology 2010, 138:1836-1844.
73. Ando T., Yoshida T., Enomoto S., Asada K., Tatematsu M., Ichinose M., et al. DNA methylation of microRNA genes in gastric mucosae of gastric cancer patients: its possible involvement in the formation of epigenetic field defect. Int J Cancer 2009, 124:2367-2374.
74. Suzuki H., Yamamoto E., Nojima M., Kai M., Yamano H.O., Yoshikawa K., et al. Methylation-associated silencing of microRNA-34b/c in gastric cancer and its involvement in an epigenetic field defect. Carcinogenesis 2010, 31:2066-2073.
75. Craig V.J., Cogliatti S.B., Rehrauer H., Wundisch T., Muller A. Epigenetic silencing of microRNA-203 dysregulates ABL1 expression and drives Helicobacter-associated gastric lymphomagenesis. Cancer Res 2011, 71:3616-3624.
76. Matsushima K., Isomoto H., Inoue N., Nakayama T., Hayashi T., Nakayama M., et al. MicroRNA signatures in Helicobacter pylori-infected gastric mucosa. Int J Cancer 2011, 128:361-370.
77. Schlesinger Y., Straussman R., Keshet I., Farkash S., Hecht M., Zimmerman J., et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 2007, 39:232-236.
78. Widschwendter M., Fiegl H., Egle D., Mueller-Holzner E., Spizzo G., Marth C., et al. Epigenetic stem cell signature in cancer. Nat Genet 2007, 39:157-158.
79. Ballestar E., Esteller M. Epigenetic gene regulation in cancer. Adv Genet 2008, 61:247-267.
80. Hahn M.A., Hahn T., Lee D.H., Esworthy R.S., Kim B.W., Riggs A.D., et al. Methylation of polycomb target genes in intestinal cancer is mediated by inflammation. Cancer Res 2008, 68:10280-10289.
81. Pathak S.K., Basu S., Bhattacharyya A., Pathak S., Banerjee A., Basu J., et al. TLR4-dependent NF-kappaB activation and mitogen- and stress-activated protein kinase 1-triggered phosphorylation events are central to Helicobacter pylori peptidyl prolyl cis-, trans-isomerase (HP0175)-mediated induction of IL-6 release from macrophages. J Immunol 2006, 177:7950-7958.
82. Fehri L.F., Rechner C., Janssen S., Mak T.N., Holland C., Bartfeld S., et al. Helicobacter pylori-induced modification of the histone H3 phosphorylation status in gastric epithelial cells reflects its impact on cell cycle regulation. Epigenetics 2009, 4:577-586.
83. Ding S.Z., Fischer W., Kaparakis-Liaskos M., Liechti G., Merrell D.S., Grant P.A., et al. Helicobacter pylori-induced histone modification, associated gene expression in gastric epithelial cells, and its implication in pathogenesis. PLoS ONE 2010, 5. e9875.
84. Tolg C., Sabha N., Cortese R., Panchal T., Ahsan A., Soliman A., et al. Uropathogenic E. coli infection provokes epigenetic downregulation of CDKN2A (p16INK4A) in uroepithelial cells. Lab Invest 2011, 91:825-836.
85. Murata M., Azuma Y., Miura K., Rahman M.A., Matsutani M., Aoyama M., et al. Chlamydial SET domain protein functions as a histone methyltransferase. Microbiology 2007, 153:585-592.
86. Pennini M.E., Perrinet S., Dautry-Varsat A., Subtil A. Histone methylation by NUE, a novel nuclear effector of the intracellular pathogen Chlamydia trachomatis. PLoS Pathog 2010, 6. e1000995.
87. Niller H.H., Wolf H., Minarovits J. Epstein-Barr Virus. Latency Strategies of Herpesviruses 2007, 154-191. Springer, New York. J. Minarovits, E. Gonczol, T. Valyi-Nagy (Eds.).
88. Swaminathan S. Noncoding RNAs produced by oncogenic human herpesviruses. J Cell Physiol 2008, 216:321-326.
89. Tempera I., Klichinsky M., Lieberman P.M. EBV latency types adopt alternative chromatin conformations. PLoS Pathog 2011, 7. e1002180.
90. Wang L., Grossman S.R., Kieff E. Epstein-Barr virus nuclear protein 2 interacts with p300, CBP, and PCAF histone acetyltransferases in activation of the LMP1 promoter. Proc Natl Acad Sci USA 2000, 97:430-435.
91. Portal D., Rosendorff A., Kieff E. Epstein-Barr nuclear antigen leader protein coactivates transcription through interaction with histone deacetylase 4. Proc Natl Acad Sci USA 2006, 103:19278-19283.
92. Cotter M.A., Robertson E.S. Modulation of histone acetyltransferase activity through interaction of Epstein-Barr nuclear antigen 3C with prothymosin alpha. Mol Cell Biol 2000, 20:5722-5735.
93. Subramanian C., Hasan S., Rowe M., Hottiger M., Orre R., Robertson E.S. Epstein-Barr virus nuclear antigen 3C and prothymosin alpha interact with the p300 transcriptional coactivator at the CH1 and CH3/HAT domains and cooperate in regulation of transcription and histone acetylation. J Virol 2002, 76:4699-4708.
94. Knight J.S., Lan K., Subramanian C., Robertson E.S. Epstein-Barr virus nuclear antigen 3C recruits histone deacetylase activity and associates with the corepressors mSin3A and NCoR in human B-cell lines. J Virol 2003, 77:4261-4272.
95. Skalska L., White R.E., Franz M., Ruhmann M., Allday M.J. Epigenetic repression of p16(INK4A) by latent Epstein-Barr virus requires the interaction of EBNA3A and EBNA3C with CtBP. PLoS Pathog 2010, 6. e1000951.
96. Anderton E., Yee J., Smith P., Crook T., White R.E., Allday M.J. Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt's lymphoma. Oncogene 2008, 27:421-433.
97. Paschos K., Smith P., Anderton E., Middeldorp J.M., White R.E., Allday M.J. Epstein-Barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim. PLoS Pathog 2009, 5. e1000492.
98. Tsai C.N., Tsai C.L., Tse K.P., Chang H.Y., Chang Y.S. The Epstein-Barr virus oncogene product, latent membrane protein 1, induces the downregulation of E-cadherin gene expression via activation of DNA methyltransferases. Proc Natl Acad Sci USA 2002, 99:10084-10089.
99. Tsai C.L., Li H.P., Lu Y.J., Hsueh C., Liang Y., Chen C.L., et al. Activation of DNA methyltransferase 1 by EBV LMP1 Involves c-Jun NH(2)-terminal kinase signaling. Cancer Res 2006, 66:11668-11676.
100. Dutton A., Woodman C.B., Chukwuma M.B., Last J.I., Wei W., Vockerodt M., et al. Bmi-1 is induced by the Epstein-Barr virus oncogene LMP1 and regulates the expression of viral target genes in Hodgkin lymphoma cells. Blood 2007, 109:2597-2603.
101. Niller H.H., Wolf H., Minarovits J. Epigenetic dysregulation of the host cell genome in Epstein-Barr virus-associated neoplasia. Semin Cancer Biol 2009, 19:158-164.
102. Kwong J., Lo K.W., To K.F., Teo P.M., Johnson P.J., Huang D.P. Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin Cancer Res 2002, 8:131-137.
103. Murray P.G., Qiu G.H., Fu L., Waites E.R., Srivastava G., Heys D., et al. Frequent epigenetic inactivation of the RASSF1A tumor suppressor gene in Hodgkin's lymphoma. Oncogene 2004, 23:1326-1331.
104. Doerr J.R., Malone C.S., Fike F.M., Gordon M.S., Soghomonian S.V., Thomas R.K., et al. Patterned CpG methylation of silenced B cell gene promoters in classical Hodgkin lymphoma-derived and primary effusion lymphoma cell lines. J Mol Biol 2005, 350:631-640.
105. Ushmorov A., Leithauser F., Sakk O., Weinhausel A., Popov S.W., Moller P., et al. Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma. Blood 2006, 107:2493-2500.
106. Rossi D., Gaidano G., Gloghini A., Deambrogi C., Franceschetti S., Berra E., et al. Frequent aberrant promoter hypermethylation of O6-methylguanine-DNA methyltransferase and death-associated protein kinase genes in immunodeficiency-related lymphomas. Br J Haematol 2003, 123:475-478.
107. Au W.Y., Ma E.S., Choy C., Chung L.P., Fung T.K., Liang R., et al. Therapy-related lymphomas in patients with autoimmune diseases after treatment with disease-modifying anti-rheumatic drugs. Am J Hematol 2006, 81:5-11.
108. Hino R., Uozaki H., Murakami N., Ushiku T., Shinozaki A., Ishikawa S., et al. Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma. Cancer Res 2009, 69:2766-2774.
109. Georgescu M.M. PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control. Genes Cancer 2010, 1:1170-1177.
110. Kang G.H., Lee S., Kim W.H., Lee H.W., Kim J.C., Rhyu M.G., et al. Epstein-Barr virus-positive gastric carcinoma demonstrates frequent aberrant methylation of multiple genes and constitutes CpG island methylator phenotype-positive gastric carcinoma. Am J Pathol 2002, 160:787-794.
111. Chang M.S., Uozaki H., Chong J.M., Ushiku T., Sakuma K., Ishikawa S., et al. CpG island methylation status in gastric carcinoma with and without infection of Epstein-Barr virus. Clin Cancer Res 2006, 12:2995-3002.
112. Luo B., Wang Y., Wang X.F., Liang H., Yan L.P., Huang B.H., et al. Expression of Epstein-Barr virus genes in EBV-associated gastric carcinomas. World J Gastroenterol 2005, 11:629-633.
113. Pantry S.N., Medveczky P.G. Epigenetic regulation of Kaposi's sarcoma-associated herpesvirus replication. Semin Cancer Biol 2009, 19:153-157.
114. Stedman W., Deng Z., Lu F., Lieberman P.M. ORC, MCM, and histone hyperacetylation at the Kaposi's sarcoma-associated herpesvirus latent replication origin. J Virol 2004, 78:12566-12575.
115. Sakakibara S., Ueda K., Nishimura K., Do E., Ohsaki E., Okuno T., et al. Accumulation of heterochromatin components on the terminal repeat sequence of Kaposi's sarcoma-associated herpesvirus mediated by the latency-associated nuclear antigen. J Virol 2004, 78:7299-7310.
116. Gunther T., Grundhoff A. The epigenetic landscape of latent Kaposi sarcoma-associated herpesvirus genomes. PLoS Pathog 2010, 6. e1000935.
117. Toth Z., Maglinte D.T., Lee S.H., Lee H.R., Wong L.Y., Brulois K.F., et al. Epigenetic analysis of KSHV latent and lytic genomes. PLoS Pathog 2010, 6. e1001013.
118. Kang H., Wiedmer A., Yuan Y., Robertson E., Lieberman P.M. Coordination of KSHV latent and lytic gene control by CTCF-cohesin mediated chromosome conformation. PLoS Pathog 2011, 7. e1002140.
119. Lu F., Stedman W., Yousef M., Renne R., Lieberman P.M. Epigenetic regulation of Kaposi's sarcoma-associated herpesvirus latency by virus-encoded microRNAs that target Rta and the cellular Rbl2-DNMT pathway. J Virol 2010, 84:2697-2706.
120. Shamay M., Krithivas A., Zhang J., Hayward S.D. Recruitment of the de novo DNA methyltransferase Dnmt3a by Kaposi's sarcoma-associated herpesvirus LANA. Proc Natl Acad Sci USA 2006, 103:14554-14559.
121. Di Bartolo D.L., Cannon M., Liu Y.F., Renne R., Chadburn A., et al. KSHV LANA inhibits TGF-beta signaling through epigenetic silencing of the TGF-beta type II receptor. Blood 2008, 111:4731-4740.
122. Krithivas A., Young D.B., Liao G., Greene D., Hayward S.D. Human herpesvirus 8 LANA interacts with proteins of the mSin3 corepressor complex and negatively regulates Epstein-Barr virus gene expression in dually infected PEL cells. J Virol 2000, 74:9637-9645.
123. Lim C., Lee D., Seo T., Choi C., Choe J. Latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus functionally interacts with heterochromatin protein 1. J Biol Chem 2003, 278:7397-7405.
124. Stuber G., Mattsson K., Flaberg E., Kati E., Markasz L., Sheldon J.A., et al. HHV-8 encoded LANA-1 alters the higher organization of the cell nucleus. Mol Cancer 2007, 6:28.
125. Matsumura S., Persson L.M., Wong L., Wilson A.C. The latency-associated nuclear antigen interacts with MeCP2 and nucleosomes through separate domains. J Virol 2010, 84:2318-2330.
126. Platt G., Carbone A., Mittnacht S. p16INK4a loss and sensitivity in KSHV associated primary effusion lymphoma. Oncogene 2002, 21:1823-1831.
127. Carbone A., Cilia A.M., Gloghini A., Capello D., Fassone L., Perin T., et al. Characterization of a novel HHV-8-positive cell line reveals implications for the pathogenesis and cell cycle control of primary effusion lymphoma. Leukemia 2000, 14:1301-1309.
128. Gonczol E., Andrews P.W., Plotkin S.A. Cytomegalovirus replicates in differentiated but not in undifferentiated human embryonal carcinoma cells. Science 1984, 224:159-161.
129. Murphy J.C., Fischle W., Verdin E., Sinclair J.H. Control of cytomegalovirus lytic gene expression by histone acetylation. EMBO J 2002, 21:1112-1120.
130. Wright E., Bain M., Teague L., Murphy J., Sinclair J. Ets-2 repressor factor recruits histone deacetylase to silence human cytomegalovirus immediate-early gene expression in non-permissive cells. J Gen Virol 2005, 86:535-544.
131. Park J.J., Kim Y.E., Pham H.T., Kim E.T., Chung Y.H., Ahn J.H. Functional interaction of the human cytomegalovirus IE2 protein with histone deacetylase 2 in infected human fibroblasts. J Gen Virol 2007, 88:3214-3223.
132. Nevels M., Paulus C., Shenk T. Human cytomegalovirus immediate-early 1 protein facilitates viral replication by antagonizing histone deacetylation. Proc Natl Acad Sci USA 2004, 101:17234-17239.
133. Hayhurst G.P., Bryant L.A., Caswell R.C., Walker S.M., Sinclair J.H. CCAAT box-dependent activation of the TATA-less human DNA polymerase alpha promoter by the human cytomegalovirus 72-kilodalton major immediate-early protein. J Virol 1995, 69:182-188.
134. Caswell R., Bryant L., Sinclair J. Human cytomegalovirus immediate-early 2 (IE2) protein can transactivate the human hsp70 promoter by alleviation of Dr1-mediated repression. J Virol 1996, 70:4028-4037.
135. Straat K., Liu C., Rahbar A., Zhu Q., Liu L., Wolmer-Solberg N., et al. Activation of telomerase by human cytomegalovirus. J Natl Cancer Inst 2009, 101:488-497.
136. Michaelis M., Doerr H.W., Cinatl J. The story of human cytomegalovirus and cancer: increasing evidence and open questions. Neoplasia 2009, 11:1-9.
137. Matsuoka M. Human T-cell leukemia virus type I (HTLV-I) infection and the onset of adult T-cell leukemia (ATL). Retrovirology 2005, 2:27.
138. Lezin A., Gillet N., Olindo S., Signate A., Grandvaux N., Verlaeten O., et al. Histone deacetylase mediated transcriptional activation reduces proviral loads in HTLV-1 associated myelopathy/tropical spastic paraparesis patients. Blood 2007, 110:3722-3728.
139. Sato H., Oka T., Shinnou Y., Kondo T., Washio K., Takano M., et al. Multi-step aberrant CpG island hyper-methylation is associated with the progression of adult T-cell leukemia/lymphoma. Am J Pathol 2010, 176:402-415.
140. Nakase K., Cheng J., Zhu Q., Marasco W.A. Mechanisms of SHP-1 P2 promoter regulation in hematopoietic cells and its silencing in HTLV-1-transformed T cells. J Leukoc Biol 2009, 85:165-174.
141. Niller H.H., Wolf H., Minarovits J. Viral hit and run-oncogenesis: Genetic and epigenetic scenarios. Cancer Lett 2011, 305:200-217.
142. Aoki Y., Tosato G. Neoplastic conditions in the context of HIV-1 infection. Curr HIV Res 2004, 2:343-349.
143. Grulich A.E., van Leeuwen M.T., Falster M.O., Vajdic C.M. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007, 370:59-67.
144. Elgui de Oliveira D. DNA viruses in human cancer: an integrated overview on fundamental mechanisms of viral carcinogenesis. Cancer Lett 2007, 247:182-196.
145. Finzi D., Hermankova M., Pierson T., Carruth L.M., Buck C., Chaisson R.E., et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278:1295-1300.
146. Siliciano J.D., Kajdas J., Finzi D., Quinn T.C., Chadwick K., Margolick J.B., et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003, 9:727-728.
147. Richman D.D., Margolis D.M., Delaney M., Greene W.C., Hazuda D., Pomerantz R.J. The challenge of finding a cure for HIV infection. Science 2009, 323:1304-1307.
148. Margolis D.M. Mechanisms of HIV latency: an emerging picture of complexity. Curr HIV/AIDS Rep 2010, 7:37-43.
149. Bednarik D.P., Mosca J.D., Raj N.B. Methylation as a modulator of expression of human immunodeficiency virus. J Virol 1987, 61:1253-1257.
150. Bednarik D.P., Cook J.A., Pitha P.M. Inactivation of the HIV LTR by DNA CpG methylation: evidence for a role in latency. EMBO J 1990, 9:1157-1164.
151. Schulze-Forster K., Gotz F., Wagner H., Kroger H., Simon D. Transcription of HIV1 is inhibited by DNA methylation. Biochem Biophys Res Commun 1990, 168:141-147.
152. Van Lint C., Emiliani S., Ott M., Verdin E. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J 1996, 15:1112-1120.
153. Coull J.J., Romerio F., Sun J.M., Volker J.L., Galvin K.M., Davie J.R., et al. The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J Virol 2000, 74:6790-6799.
154. Ylisastigui L., Archin N.M., Lehrman G., Bosch R.J., Margolis D.M. Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS 2004, 18:1101-1108.
155. Friedman J., Cho W.K., Chu C.K., Keedy K.S., Archin N.M., Margolis D.M., et al. Epigenetic Silencing of HIV-1 by the Histone H3 Lysine 27 Methyltransferase Enhancer of Zeste 2. J Virol 2011, 85:9078-9089.
156. Jiang G., Espeseth A., Hazuda D.J., Margolis D.M. c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J Virol 2007, 81:10914-10923.
157. Tyagi M., Karn J. CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency. EMBO J 2007, 26:4985-4995.
158. Schroder A.R., Shinn P., Chen H., Berry C., Ecker J.R., Bushman F. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 2002, 110:521-529.
159. Han Y., Lassen K., Monie D., Sedaghat A.R., Shimoji S., Liu X., et al. Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J Virol 2004, 78:6122-6133.
160. Han Y., Lin Y.B., An W., Xu J., Yang H.C., O'Connell K., et al. Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough. Cell Host Microbe 2008, 4:134-146.
161. Klase Z., Kale P., Winograd R., Gupta M.V., Heydarian M., Berro R., et al. HIV-1 TAR element is processed by Dicer to yield a viral micro-RNA involved in chromatin remodeling of the viral LTR. BMC Mol Biol 2007, 8:63.
162. Huang J., Wang F., Argyris E., Chen K., Liang Z., Tian H., et al. Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat Med 2007, 13:1241-1247.
163. Mikovits J.A., Young H.A., Vertino P., Issa J.P., Pitha P.M., Turcoski-Corrales S., et al. Infection with human immunodeficiency virus type 1 upregulates DNA methyltransferase, resulting in de novo methylation of the gamma interferon (IFN-gamma) promoter and subsequent downregulation of IFN-gamma production. Mol Cell Biol 1998, 18:5166-5177.
164. Fang J.Y., Mikovits J.A., Bagni R., Petrow-Sadowski C.L., Ruscetti F.W. Infection of lymphoid cells by integration-defective human immunodeficiency virus type 1 increases de novo methylation. J Virol 2001, 75:9753-9761.
165. Giordanengo V., Ollier L., Lanteri M., Lesimple J., March D., Thyss S., et al. Epigenetic reprogramming of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE) in HIV-1-infected CEM T cells. FASEB J 2004, 18:1961-1963.
166. Youngblood B., Reich N.O. The early expressed HIV-1 genes regulate DNMT1 expression. Epigenetics 2008, 3:149-156.
167. Saiyed Z.M., Gandhi N., Agudelo M., Napuri J., Samikkannu T., Reddy P.V., et al. HIV-1 Tat upregulates expression of histone deacetylase-2 (HDAC2) in human neurons: implication for HIV-associated neurocognitive disorder (HAND). Neurochem Int 2011, 58:656-664.
168. Tischoff I., Tannapfel A. DNA methylation in hepatocellular carcinoma. World J Gastroenterol 2008, 14:1741-1748.
169. Shim Y.H., Yoon G.S., Choi H.J., Chung Y.H., Yu E. p16 Hypermethylation in the early stage of hepatitis B virus-associated hepatocarcinogenesis. Cancer Lett 2003, 190:213-219.
170. Um T.H., Kim H., Oh B.K., Kim M.S., Kim K.S., Jung G., et al. Aberrant CpG island hypermethylation in dysplastic nodules and early HCC of hepatitis B virus-related human multistep hepatocarcinogenesis. J Hepatol 2011, 54:939-947.
171. Doria M., Klein N., Lucito R., Schneider R.J. The hepatitis B virus HBx protein is a dual specificity cytoplasmic activator of Ras and nuclear activator of transcription factors. EMBO J 1995, 14:4747-4757.
172. Haviv I., Shamay M., Doitsh G., Shaul Y. Hepatitis B virus pX targets TFIIB in transcription coactivation. Mol Cell Biol 1998, 18:1562-1569.
173. Benn J., Schneider R.J. Hepatitis B virus HBx protein activates Ras-GTP
174. Choi B.H., Choi M., Jeon H.Y., Rho H.M. Hepatitis B viral X protein overcomes inhibition of E2F1 activity by pRb on the human Rb gene promoter. DNA Cell Biol 2001, 20:75-80.
175. Wang W.H., Hullinger R.L., Andrisani O.M. Hepatitis B virus X protein via the p38MAPK pathway induces E2F1 release and ATR kinase activation mediating p53 apoptosis. J Biol Chem 2008, 283:25455-25467.
176. Jung J.K., Arora P., Pagano J.S., Jang K.L. Expression of DNA methyltransferase 1 is activated by hepatitis B virus X protein via a regulatory circuit involving the p16INK4a-cyclin D1-CDK 4/6-pRb-E2F1 pathway. Cancer Res 2007, 67:5771-5778.
177. Zhu Y.Z., Zhu R., Shi L.G., Mao Y., Zheng G.J., Chen Q., et al. Hepatitis B virus X protein promotes hypermethylation of p16(INK4A) promoter through upregulation of DNA methyltransferases in hepatocarcinogenesis. Exp Mol Pathol 2010, 89:268-275.
178. Park I.Y., Sohn B.H., Yu E., Suh D.J., Chung Y.H., Lee J.H., et al. Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein. Gastroenterology 2007, 132:1476-1494.
179. Ehrlich M. DNA hypomethylation and cancer. DNA Alterations in Cancer 2000, 273-291. Eaton Publishing, Westborough. M. Ehrlich (Ed.).
180. Baylin S.B., Herman J.G. Epigenetics and loss of gene function in cancer. DNA Alterations in Cancer 2000, 293-309. Eaton Publishing, Westborough. M. Ehrlich (Ed.).
181. Nagai H., Baba M., Konishi N., Kim Y.S., Nogami M., Okumura K., et al. Isolation of NotI clusters hypomethylated in HBV-integrated hepatocellular carcinomas by two-dimensional electrophoresis. DNA Res 1999, 6:219-225.
182. Wei Y., Van Nhieu J.T., Prigent S., Srivatanakul P., Tiollais P., et al. Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, beta-catenin expression, and clinical features. Hepatology 2002, 36:692-701.
183. Lee J.O., Kwun H.J., Jung J.K., Choi K.H., Min D.S., Jang K.L. Hepatitis B virus X protein represses E-cadherin expression via activation of DNA methyltransferase 1. Oncogene 2005, 24:6617-6625.
184. Liu J., Lian Z., Han S., Waye M.M., Wang H., Wu M.C., et al. Downregulation of E-cadherin by hepatitis B virus X antigen in hepatocellullar carcinoma. Oncogene 2006, 25:1008-1017.
185. Zhong S., Yeo W., Tang M.W., Wong N., Lai P.B., Johnson P.J. Intensive hypermethylation of the CpG island of Ras association domain family 1A in hepatitis B virus-associated hepatocellular carcinomas. Clin Cancer Res 2003, 9:3376-3382.
186. Zhong S., Tang M.W., Yeo W., Liu C., Lo Y.M., Johnson P.J. Silencing of GSTP1 gene by CpG island DNA hypermethylation in HBV-associated hepatocellular carcinomas. Clin Cancer Res 2002, 8:1087-1092.
187. Feng Q., Stern J.E., Hawes S.E., Lu H., Jiang M., Kiviat N.B. DNA methylation changes in normal liver tissues and hepatocellular carcinoma with different viral infection. Exp Mol Pathol 2010, 88:287-292.
188. Ahmed R., Salama H., Fouad A., Sabry D., AbdAlah e., Kamal M. Detection of aberrant p16INK4A methylation in sera of patients with HCV-related liver diseases: An Egyptian study. Med Sci Monit 2010, 16:CR410-CR415.
189. Formeister E.J., Tsuchiya M., Fujii H., Shpyleva S., Pogribny I.P., Rusyn I. Comparative analysis of promoter methylation and gene expression endpoints between tumorous and non-tumorous tissues from HCV-positive patients with hepatocellular carcinoma. Mutat Res 2010, 692:26-33.
190. Lambert M.P., Paliwal A., Vaissiere T., Chemin I., Zoulim F., Tommasino M., et al. Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intake. J Hepatol 2011, 54:705-715.
191. Herceg Z., Paliwal A. Epigenetic mechanisms in hepatocellular carcinoma: how environmental factors influence the epigenome. Mutat Res 2011, 727:55-61.
192. Yang B., Guo M., Herman J.G., Clark D.P. Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol 2003, 163:1101-1107.
193. Archer K.J., Mas V.R., Maluf D.G., Fisher R.A. High-throughput assessment of CpG site methylation for distinguishing between HCV-cirrhosis and HCV-associated hepatocellular carcinoma. Mol Genet Genomics 2010, 283:341-349.
194. Duong F.H., Christen V., Lin S., Heim M.H. Hepatitis C virus-induced up-regulation of protein phosphatase 2A inhibits histone modification and DNA damage repair. Hepatology 2010, 51:741-751.
195. Higgs M.R., Lerat H., Pawlotsky J.M. Downregulation of Gadd45beta expression by hepatitis C virus leads to defective cell cycle arrest. Cancer Res 2010, 70:4901-4911.
196. Lu C.Y., Hsieh S.Y., Lu Y.J., Wu C.S., Chen L.C., Lo S.J., et al. Aberrant DNA methylation profile and frequent methylation of KLK10 and OXGR1 genes in hepatocellular carcinoma. Genes Chromosomes Cancer 2009, 48:1057-1068.
197. Deng Y.B., Nagae G., Midorikawa Y., Yagi K., Tsutsumi S., Yamamoto S., et al. Identification of genes preferentially methylated in hepatitis C virus-related hepatocellular carcinoma. Cancer Sci 2010, 101:1501-1510.
198. Miyoshi H., Fujie H., Shintani Y., Tsutsumi T., Shinzawa S., Makuuchi M., et al. Hepatitis C virus core protein exerts an inhibitory effect on suppressor of cytokine signaling (SOCS)-1 gene expression. J Hepatol 2005, 43:757-763.
199. Ko E., Kim S.J., Joh J.W., Park C.K., Park J., Kim D.H. CpG island hypermethylation of SOCS-1 gene is inversely associated with HBV infection in hepatocellular carcinoma. Cancer Lett 2008, 271:240-250.
200. Arora P., Kim E.O., Jung J.K., Jang K.L. Hepatitis C virus core protein downregulates E-cadherin expression via activation of DNA methyltransferase 1 and 3b. Cancer Lett 2008, 261:244-252.
201. Ripoli M., Barbano R., Balsamo T., Piccoli C., Brunetti V., Coco M., et al. Hypermethylated levels of E-cadherin promoter in Huh-7 cells expressing the HCV core protein. Virus Res 2011, 160:74-81.
202. Naka K., Abe K., Takemoto K., Dansako H., Ikeda M., Shimotohno K., et al. Epigenetic silencing of interferon-inducible genes is implicated in interferon resistance of hepatitis C virus replicon-harboring cells. J Hepatol 2006, 44:869-878.
203. Magerl C., Ellinger J., Braunschweig T., Kremmer E., Koch L.K., Holler T., et al. H3K4 dimethylation in hepatocellular carcinoma is rare compared with other hepatobiliary and gastrointestinal carcinomas and correlates with expression of the methylase Ash2 and the demethylase LSD1. Hum Pathol 2010, 41:181-189.
204. Guo N., Chen R., Li Z., Liu Y., Cheng D., Zhou Q., et al. Hepatitis C virus core upregulates the methylation status of the RASSF1A promoter through regulation of SMYD3 in hilar cholangiocarcinoma cells. Acta Biochim Biophys Sin (Shanghai) 2011, 43:354-361.
205. Szalmas A., Konya J. Epigenetic alterations in cervical carcinogenesis. Semin Cancer Biol 2009, 19:144-152.
206. Henken F.E., Wilting S.M., Overmeer R.M., van Rietschoten J.G., Nygren A.O., et al. Sequential gene promoter methylation during HPV-induced cervical carcinogenesis. Br J Cancer 2007, 97:1457-1464.
207. Burgers W.A., Blanchon L., Pradhan S., de Launoit Y., Kouzarides T., Fuks F. Viral oncoproteins target the DNA methyltransferases. Oncogene 2007, 26:1650-1655.
208. Laurson J., Khan S., Chung R., Cross K., Raj K. Epigenetic repression of E-cadherin by human papillomavirus 16 E7 protein. Carcinogenesis 2010, 31:918-926.
209. Stephen J.K., Chen K.M., Shah V., Schweitzer V.G., Gardner G., Benninger M.S., et al. Consistent DNA hypermethylation patterns in laryngeal papillomas. Int J Head Neck Surg 2010, 1:69-77.
210. Holland D., Hoppe-Seyler K., Schuller B., Lohrey C., Maroldt J., Durst M., et al. Activation of the enhancer of zeste homologue 2 gene by the human papillomavirus E7 oncoprotein. Cancer Res 2008, 68:9964-9972.
211. Zhang B., Laribee R.N., Klemsz M.J., Roman A. Human papillomavirus type 16 E7 protein increases acetylation of histone H3 in human foreskin keratinocytes. Virology 2004, 329:189-198.
212. McLaughlin-Drubin M.E., Crum C.P., Munger K. Human papillomavirus E7 oncoprotein induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming. Proc Natl Acad Sci USA 2011, 108:2130-2135.
213. Feng H., Shuda M., Chang Y., Moore P.S. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 2008, 319:1096-1100.
214. Shuda M., Feng H., Kwun H.J., Rosen S.T., Gjoerup O., Moore P.S., et al. T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus. Proc Natl Acad Sci USA 2008, 105:16272-16277.
215. Ben Arie N., Hassan B.A., Bermingham N.A., Malicki D.M., Armstrong D., Matzuk M., et al. Functional conservation of atonal and Math1 in the CNS and PNS. Development 2000, 127:1039-1048.
216. Bossuyt W., Kazanjian A., De Geest N., Van Kelst S., De Hertogh G., Geboes K., et al. Atonal homolog 1 is a tumor suppressor gene. PLoS Biol 2009, 7. e39.
217. Helmbold P., Lahtz C., Enk A., Herrmann-Trost P., Marsch W.C., Kutzner H., et al. Frequent occurrence of RASSF1A promoter hypermethylation and Merkel cell polyomavirus in Merkel cell carcinoma. Mol Carcinog 2009, 48:903-909.
218. Vatanasapt V., Uttaravichien T., Mairiang E.O., Pairojkul C., Chartbanchachai W., Haswell-Elkins M. Cholangiocarcinoma in north-east Thailand. Lancet 1990, 335:116-117.
219. Shin H.R., Oh J.K., Masuyer E., Curado M.P., Bouvard V., Fang Y.Y., et al. Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer Sci 2010, 101:579-585.
220. Chinnasri P., Pairojkul C., Jearanaikoon P., Sripa B., Bhudhisawasdi V., Tantimavanich S., et al. Preferentially different mechanisms of inactivation of 9p21 gene cluster in liver fluke-related cholangiocarcinoma. Hum Pathol 2009, 40:817-826.
221. Sriraksa R., Zeller C., El Bahrawy M.A., Dai W., Daduang J., et al. CpG-island methylation study of liver fluke-related cholangiocarcinoma. Br J Cancer 2011, 104:1313-1318.
222. Fantappie M.R., Gimba E.R., Rumjanek F.D. Lack of DNA methylation in Schistosoma mansoni. Exp Parasitol 2001, 98:162-166.
223. Gutierrez M.I., Siraj A.K., Khaled H., Koon N., El Rifai W., Bhatia K. CpG island methylation in Schistosoma- and non-Schistosoma-associated bladder cancer. Mod Pathol 2004, 17:1268-1274.
224. Niller H.H., Wolf H., Minarovits J. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases. Autoimmunity 2008, 41:298-328.
225. North M.L., Ellis A.K. The role of epigenetics in the developmental origins of allergic disease. Ann Allergy Asthma Immunol 2011, 106:355-361.
226. Licciardi P.V., Wong S.S., Tang M.L., Karagiannis T.C. Epigenome targeting by probiotic metabolites. Gut Pathog 2010, 2:24.